Epigenetic regulation of osteoclast differentiation

Annals of the New York Academy of Sciences

Volumn 1240, Issue 1, 2011, Pages 7-13

  Yasui, Tetsuro ^a   Hirose, Jun ^a   Aburatani, Hiroyuki ^b   Tanaka, Sakae ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Differentiation; Epigenetics; Histone modification; Jmjd3; Osteoclast

Indexed keywords

HISTONE DEMETHYLASE; HISTONE H3; LYSINE; MICRORNA; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ARTICLE; CELL STIMULATION; CPG ISLAND; DEMETHYLATION; ENZYME ACTIVATION; ENZYME INDUCTION; EPIGENETICS; GENE EXPRESSION REGULATION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; MACROPHAGE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PROTEIN DOMAIN; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 83755206832     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06245.x     Document Type: Article

References (46)

1. Bird, A. 2007. Perceptions of epigenetics. Nature 447: 396-398.
2. Barski, A. et al. 2007. High-resolution profiling of histone methylations in the human genome. Cell 129: 823-837.
3. Cokus, S.J. et al. 2008. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature 452: 215-219.
4. Hotchkiss, R.D. 1948. The quantitative separation of purines, pyrimidines, and nucleosides by paper chromatography. J. Biol. Chem. 175: 315-332.
5. Jaenisch, R. & A. Bird. 2003. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33(Suppl): 245-254.
6. Feinberg, A.P. 2007. Phenotypic plasticity and the epigenetics of human disease. Nature 447: 433-440.
7. Feinberg, A.P. & B. Tycko. 2004. The history of cancer epigenetics. Nat. Rev. Cancer 4: 143-153.
8. Doi, A. et al. 2009. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41: 1350-1353.
9. Ji, H. et al. 2010. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 467: 338-342.
10. Molina, T.J. et al. 1992. Profound block in thymocyte development in mice lacking p56lck. Nature 357: 161-164.
11. Luger, K. et al. 1997. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389: 251-260.
12. Jenuwein, T. & C.D. Allis. 2001. Translating the histone code. Science 293: 1074-1080.
13. Zardo, G., G. Cimino & C. Nervi. 2008. Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming. Leukemia 22: 1503-1518.
14. Esteller, M. 2008. Epigenetics in cancer. N. Eng. J. Med. 358: 1148-1159.
15. Roh, T.Y. et al. 2006. The genomic landscape of histone modifications in human T cells. Proc. Natl. Acad. Sci. USA 103: 15782-15787.
16. Cui, K. et al. 2009. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell 4: 80-93.
17. Yu, H. et al. 2008. Inferring causal relationships among different histone modifications and gene expression. Genome Res. 18: 1314-1324.
18. Strahl, B.D. & C.D. Allis. 2000. The language of covalent histone modifications. Nature 403: 41-45.
19. Azuara, V. et al. 2006. Chromatin signatures of pluripotent cell lines. Nat. Cell Biol. 8: 532-538.
20. Bernstein, B.E. et al. 2006. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125: 315-326.
21. Agger, K. et al. 2007. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449: 731-734.
22. Hong, S. et al. 2007. Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc. Natl. Acad. Sci. USA 104: 18439-18444.
23. Satoh, T. et al. 2010. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat. Immunol. 11: 936-944.
24. Sen, G.L. et al. 2008. Control of differentiation in a self-renewing mammalian tissue by the histone demethylase JMJD3. Genes Dev. 22: 1865-1870.
25. Kim, T.K. et al. 2010. Widespread transcription at neuronal activity-regulated enhancers. Nature 465: 182-187.
26. Morris, K.V. 2009. Non-coding RNAs, epigenetic memory and the passage of information to progeny. RNA Biol. 6: 242-247.
27. Taft, R.J. et al. 2009. Tiny RNAs associated with transcription start sites in animals. Nat. Genet. 41: 572-578.
28. Ponting, C.P., P.L. Oliver & W. Reik. 2009. Evolution and functions of long noncoding RNAs. Cell 136: 629-641.
29. Bartel, D.P. & C.Z. Chen. 2004. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat. Rev. Genet. 5: 396-400.
30. Chen, K. & N. Rajewsky. 2007. The evolution of gene regulation by transcription factors and microRNAs. Nat. Rev. Genet. 8: 93-103.
31. Chen, C.Z. et al. 2004. MicroRNAs modulate hematopoietic lineage differentiation. Science 303: 83-86.
32. Zimmerman, E.I. et al. 2010. Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia. Mol. Pharmacol. 78: 811-817.
33. Boyle, W.J., W.S. Simonet & D.L. Lacey. 2003. Osteoclast differentiation and activation. Nature 423: 337-342.
34. Karsenty, G. & E.F. Wagner. 2002. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2: 389-406.
35. Teitelbaum, S.L. 2000. Bone resorption by osteoclasts. Science 289: 1504-1508.
36. Tanaka, S. et al. 2005. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol. Rev. 208: 30-49.
37. Lacey, D.L. et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
38. Yasuda, H. et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95: 3597-3602.
39. Asagiri, M. et al. 2005. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202: 1261-1269.
40. Takayanagi, H. et al. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3: 889-901.
41. Kitazawa, R. & S. Kitazawa. 2002. Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem. Biophys. Res. Commun. 290: 650-655.
42. Mizoguchi, F. et al. 2010. Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption. J. Cell Biochem. 109: 866-875.
43. Sugatani, T. & K.A. Hruska. 2009. Impaired micro-RNA pathways diminish osteoclast differentiation and function. J. Biol. Chem. 284: 4667-4678.
44. Sugatani, T., J. Vacher & K.A. Hruska. 2011. A microRNA expression signature of osteoclastogenesis. Blood 117: 3648-3657.
45. Mann, M. et al. 2010. miRNA-based mechanism for the commitment of multipotent progenitors to a single cellular fate. Proc. Natl. Acad. Sci. USA 107: 15804-15809.
46. Yasui, T. et al. 2011. Regulation of RANKL-induced osteoclastogenesis by TGF-beta through molecular interaction between Smad3 and Traf6. J. Bone Miner. Res. 26: 1447-1456.